Moreau Caroline, Trussell James, Gilbert Fabien, Bajos Nathalie, Bouyer Jean
CInstitut National de la Santé et de la Recherche Médicale, Unit 822, Department of Epidemiology, University Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France.
Obstet Gynecol. 2007 Jun;109(6):1277-85. doi: 10.1097/01.AOG.0000260956.61835.6d.
To examine the frequencies of reported symptoms by oral contraceptive pill (OCP) composition among French women.
A population-based cohort of 2,863 women studied between 2000 and 2004 was used to compare the frequency of reported symptoms (weight gain, nausea, breast tenderness, lower frequency of menstrual periods, breakthrough bleeding, painful and heavy periods, swollen legs) by type of OCPs (classified by estrogen dosage, progestin component, and sequence of administration).
Results show little variation in the frequency of symptoms by type of OCPs, with the exception of progestin-only pills being associated with higher frequencies of breakthrough bleeding and lower frequencies of menstrual periods. We found no decrease in the reporting of symptoms with the reduction of estrogen dosage, nor with the use of third-generation OCPs compared with second-generation OCPs. Likewise, we found little variation by sequence of administration of OCPs (monophasic versus triphasic).
In the absence of sufficient evidence-based data to support the existence of differences in the tolerance profile of low-dose combined OCPs, future well-designed randomized trials are needed to guide providers in their choice of OCPs. However, research should also assess the effectiveness of counseling on the tolerance of OCPs, an intervention that may prove to be more rewarding than basing the choice of OCPs on their theoretical properties.
研究法国女性中按口服避孕药(OCP)成分报告的症状出现频率。
利用2000年至2004年期间研究的2863名女性的基于人群的队列,比较按OCP类型(按雌激素剂量、孕激素成分和给药顺序分类)报告的症状(体重增加、恶心、乳房胀痛、月经周期频率降低、突破性出血、痛经和月经过多、腿部肿胀)出现频率。
结果显示,除仅含孕激素的避孕药与较高的突破性出血频率和较低的月经周期频率相关外,不同类型OCP的症状出现频率差异不大。我们发现,雌激素剂量减少以及与第二代OCP相比使用第三代OCP时,症状报告并无减少。同样,我们发现OCP给药顺序(单相与三相)的差异也不大。
由于缺乏足够的循证数据来支持低剂量复方OCP耐受性存在差异,未来需要精心设计的随机试验来指导医疗服务提供者选择OCP。然而,研究还应评估关于OCP耐受性的咨询效果,这种干预可能比基于OCP理论特性进行选择更有价值。